Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.

abstract：Background:Atherosclerosis (AS) is a common severe disease around the world. The merging paper reported that long noncoding RNAs (lncRNAs) took part in diversified pathological processes of AS, although the mechanism remains unknown. This study is aimed at uncovering the profile of lncRNA taurine-upregulated gene 1 (TU...

journal_title：Cardiovascular therapeutics

authors： Tang Y,Hu J,Zhong Z,Liu Y,Wang Y

更新日期：2020-05-29 00:00:00

abstract：BACKGROUND:Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an ...

journal_title：Cardiovascular therapeutics

authors： Cobas M,Paparcuri G,De La Pena M,Cudemus G,Barquist E,Varon A

更新日期：2011-08-01 00:00:00

abstract：BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...

journal_title：Cardiovascular therapeutics

authors： Bocchi EA,Moura LZ,Issa VS,Cruz F,Carvalho VO,Guimarães GV

更新日期：2013-04-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease is a major cause of death worldwide. Different medical and surgical therapeutic options are well established, but a significant number of patients are not amenable to standard therapeutic options. Cell-based therapies after clinical application have shown different results in recent ...

journal_title：Cardiovascular therapeutics

authors： Ghodsizad A,Ruhparwar A,Bordel V,Mirsaidighazi E,Klein HM,Koerner MM,Karck M,El-Banayosy A

更新日期：2013-12-01 00:00:00

abstract：:Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, and end-stage renal failure, which could account for disabilities and high mortality rates in patients with diabetes. Recent clinical studies have substantiated the concept of "hyperglycemic...

journal_title：Cardiovascular therapeutics

authors： Yamagishi S,Nakamura K,Matsui T,Ueda S,Noda Y,Imaizumi T

更新日期：2008-04-01 00:00:00

abstract：Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

journal_title：Cardiovascular therapeutics

authors： Sunjaya AF,Sunjaya AP

更新日期：2019-04-01 00:00:00

abstract：AIMS:Insulin promotes Akt-dependent prosurvival signaling and reduces experimental ischemia reperfusion injury, but its clinical impact has been limited. Further understanding of the interplay between insulin and Akt in the myocardium of relevant large animal models is needed. We aimed to investigate (1) Akt phosphoryl...

journal_title：Cardiovascular therapeutics

authors： Slettom G,Jonassen AK,Breivik L,Seifert R,Nordrehaug JE

更新日期：2013-12-01 00:00:00

abstract：AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

journal_title：Cardiovascular therapeutics

authors： Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

更新日期：2016-06-01 00:00:00

abstract：AIM:To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS:A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared a...

journal_title：Cardiovascular therapeutics

authors： Zhang J,Tian L,Huang J,Huang S,Chai T,Shen J

更新日期：2017-02-01 00:00:00

abstract：:Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury...

journal_title：Cardiovascular therapeutics

authors： Jang YH,Kim JH,Ban C,Ahn K,Cheong JH,Kim HH,Kim JS,Park YH,Kim J,Chun KJ,Lee GH,Kim M,Kim C,Xu Z

更新日期：2012-10-01 00:00:00

abstract：:Cilnidipine is a unique Ca(2+) channel blocker with an inhibitory action on the sympathetic N-type Ca(2+) channels, which is used for patients with hypertension in Japan. Cilnidipine has been clarified to exert antisympathetic actions in various examinations from cell to human levels, in contrast to classical Ca(2+) c...

journal_title：Cardiovascular therapeutics

authors： Takahara A

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:The systematic review and meta-analysis are to evaluate the effect of t Telmisartan on atrial fibrillation (AF) recurrences in hypertensive patients with paroxysmal AF. METHODS:MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched. Random controlled trials (RCTs) were conduct...

journal_title：Cardiovascular therapeutics

authors： Pan G,Zhou X,Zhao J

更新日期：2014-08-01 00:00:00

abstract：:Patients with coronary artery disease (CAD) commonly have varying degrees of coexisting cerebrovascular disease (CVD) and chronic kidney disease (CKD), and proper management is complicated partly because of a lack of unifying guidelines. The aim of this article is to review the current literature and propose the optim...

journal_title：Cardiovascular therapeutics

authors： Notaro LA,Usman MH,Burke JF,Siddiqui A,Superdock KR,Ezekowitz MD

更新日期：2009-10-01 00:00:00

abstract：AIMS:We performed a multicenter, randomized controlled trial to determine the noninferiority of a novel biodegradable polymer drug-eluting stent (BP-DES), the EXCEL 2 stent, to the first-generation BP-DES, the EXCEL stent. METHODS AND RESULTS:Patients (n = 419) scheduled to undergo percutaneous coronary intervention (...

journal_title：Cardiovascular therapeutics

authors： Xu K,Han Y,Xu B,Yang Y,Wang G,Li H,Sun Y,Tao L,Wang H,Yuan Z,Liu H,Liu J,Jia Y,Ma G,Fu G,Li X,Li S,Wang S,Pu K,CREDIT 2 Investigators.

更新日期：2018-06-01 00:00:00

abstract：:Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

journal_title：Cardiovascular therapeutics

authors： Cohen M,Iyer D

更新日期：2014-10-01 00:00:00

abstract：INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

journal_title：Cardiovascular therapeutics

authors： Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

更新日期：2018-12-01 00:00:00

abstract：OBJECTIVE:The transplant vasculopathy as a sign of chronic graft rejection affects both the epicardial and the intramyocardial arteries of the graft. This is at least partially mediated by NO synthases. The aim of this study was to assess possible protective effects of cyclosporine A (CsA), tacrolimus (FK506), and myco...

journal_title：Cardiovascular therapeutics

authors： Bogossian H,Frommeyer G,Ninios I,Bandorski D,Seyfarth M,Matzaroglou C,Lemke B,Eckardt L,Zarse M,Kafchitsas K

更新日期：2016-08-01 00:00:00

abstract：:The pericardium is composed of visceral and parietal components. In view of the pericardium's simple structure, pathologic processes involving it are understandably few. However, despite a limited number of clinical syndromes, the pericardium is affected by virtually every category of disease, including infectious, ne...

journal_title：Cardiovascular therapeutics

authors： Azam S,Hoit BD

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. METHODS:We ...

journal_title：Cardiovascular therapeutics

authors： Krum H,van Veldhuisen DJ,Funck-Brentano C,Vanoli E,Silke B,Erdmann E,Follath F,Ponikowski P,Goulder M,Meyer W,Lechat P,Willenheimer R,behalf of the CIBIS III Investigators.

更新日期：2011-04-01 00:00:00

abstract：:In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

journal_title：Cardiovascular therapeutics

authors： Perin EC,Silva GV

更新日期：2011-06-01 00:00:00

abstract：INTRODUCTION:Statins are known to prevent heart failure (HF). However, it is unclear whether statins as class or type (lipophilic or hydrophilic) improve outcomes of established HF. AIMS:The current meta-analysis was performed to compare the treatment effects of lipophilic and hydrophilic statins on inflammation and c...

journal_title：Cardiovascular therapeutics

authors： Bonsu KO,Reidpath DD,Kadirvelu A

更新日期：2015-12-01 00:00:00

abstract：:Alternative medications as a term call up many different meanings, significance, and perceptions to various medical practitioners. Some are good; others are bad. A wide range of alternative medications with relevance or connection to cardiovascular (CV) disease have been considered. While many are worthless, others ha...

journal_title：Cardiovascular therapeutics

authors： Whayne TF Jr

更新日期：2010-04-01 00:00:00

abstract：INTRODUCTION:Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear. AIMS:We sought to evaluate the safety and cl...

journal_title：Cardiovascular therapeutics

authors： LaRue SJ,Garcia-Cortes R,Nassif ME,Vader JM,Ray S,Ravichandran A,Rasalingham R,Silvestry SC,Ewald GA,Wang IW,Schilling JD

更新日期：2015-04-01 00:00:00

abstract：:Patients with peripheral artery disease (PAD) and critical limb ischemia are the main candidates for limb amputations and have a poor life expectancy. Frequently, these patients are not eligible for either surgical or percutaneous interventions aimed at mechanical revascularization. Therefore, new strategies need to b...

journal_title：Cardiovascular therapeutics

authors： Germani A,Di Campli C,Pompilio G,Biglioli P,Capogrossi MC

更新日期：2009-01-01 00:00:00

abstract：INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spani...

journal_title：Cardiovascular therapeutics

authors： Bardají A,Leal M,Arrarte V,Garcia-Moll X,Pérez de Isla L,Bueno H

更新日期：2017-04-01 00:00:00

abstract：BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

journal_title：Cardiovascular therapeutics

authors： Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:The metabolic modulator trimetazidine (TMZ) has been suggested to induce a metabolic shift from myocardial fatty acid oxidation (FAO) to glucose utilization, but this mechanism remains unproven in humans. The oxidation of plasma derived FA is commonly measured in humans, whereas the contribution of FA from...

journal_title：Cardiovascular therapeutics

authors： Bucci M,Borra R,Någren K,Pärkkä JP,Del Ry S,Maggio R,Tuunanen H,Viljanen T,Cabiati M,Rigazio S,Taittonen M,Pagotto U,Parkkola R,Opie LH,Nuutila P,Knuuti J,Iozzo P

更新日期：2012-12-01 00:00:00

abstract：INTRODUCTION:Nonadherence to secondary preventative medications after stroke is common and is associated with poor outcomes. Numerous strategies exist to promote adherence. We performed a systematic review and meta-analysis to describe the efficacy of strategies to improve adherence to stroke secondary prevention. MET...

journal_title：Cardiovascular therapeutics

authors： Al AlShaikh S,Quinn T,Dunn W,Walters M,Dawson J

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:Levosimendan is a noncatecholamine inotrope that does not increase oxygen consumption, utilized for the treatment for acute heart failure with left ventricular (LV) systolic dysfunction. Its use in takotsubo cardiomyopathy (TTC), a disease that contraindicates the use of catecholamine inotropes, is not well ...

journal_title：Cardiovascular therapeutics

authors： Santoro F,Ieva R,Ferraretti A,Ienco V,Carpagnano G,Lodispoto M,Di Biase L,Di Biase M,Brunetti ND

更新日期：2013-12-01 00:00:00

abstract：BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors an...

journal_title：Cardiovascular therapeutics

authors： Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

更新日期：2018-10-01 00:00:00